IT & Data Management
Aortic Stability Evaluation To Find Patients At High Risk
According to a recent study conducted in collaboration by the University of Eastern Finland and Kuopio University Hospital, patients with ascending aortic dilatation are more likely to experience pathological changes in the aortic wall when wall shear stress values...
Drug Research
FDA Wraps Up The REMS Standards For Prescription Medicines
The FDA's Final Guidance on REMS programmes for prescription medications, has just been published. The document is officially titled Format and Content of a REMS Document: Guidance for Industry.
The FDA may demand a risk management strategy known as REMS,...
Drug Research
United States-Switzerland Strike A Drug Inspection Accord
The US and Switzerland have agreed to a Mutual Recognition Agreement (MRA) on pharmaceutical Good Manufacturing Practices (GMP).
The US Food and Drug Administration (FDA) and the Swiss Agency for Therapeutic Products (Swissmedic) will be able to utilize each other's...
News
A Sizeable Increase In Healthcare Deals Anticipated In 2023
Pharma companies with plenty of cash were on one side of a $200 billion patent cliff. On the other hand, there were a lot of smaller biotech companies that were cash-strapped and offering assets at a discount. These companies'...
IT & Data Management
Addressing Diseases Through Technology – A New Revolution
To grasp the intricate pathology of many diseases today, scientists and researchers have achieved amazing advances in basic science. The ability of the human mind to think critically and come up with answers is unmatched, and some of that...
Clinical Trials
Update On The Clinical Trials Regulation Implementation
The Clinical Trial Information System went live on January 31, 2022, which began the one-year transition period for all clinical trial sponsors. Clinical trial sponsors are still free to decide whether to submit an initial clinical study application via...
IT & Data Management
5 Challenges That Will Affect Developing Biotech In 2023
Drugmakers' initial stock offerings, which had been a dependable tradition for years, mostly stopped in 2022. Fewer than two dozen biotech businesses priced initial public offerings (IPOs) last year, a 79% decrease from the total of the prior year...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.